|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 34.92M | Perf Week | 46.36% |
Market Cap | 860.66M | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.50M | Perf Month | 77.57% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 13.60% | Short Float | 1.76% | Perf Quarter | 97.52% |
Sales | - | P/S | - | EPS this Y | 72.30% | Inst Trans | - | Short Ratio | 1.45 | Perf Half Y | 65.33% |
Book/sh | 2.55 | P/B | 8.75 | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | 2.13 | P/C | 10.46 | EPS next 5Y | - | ROE | - | 52W Range | 9.91 - 22.48 | Perf YTD | 39.50% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -0.71% | Beta | - |
Dividend % | - | Quick Ratio | 22.70 | Sales past 5Y | - | Gross Margin | - | 52W Low | 125.30% | ATR | 1.60 |
Employees | 17 | Current Ratio | 22.70 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 80.19 | Volatility | 15.61% 9.78% |
Optionable | No | Debt/Eq | 0.02 | EPS Q/Q | 81.90% | Profit Margin | - | Rel Volume | 1.88 | Prev Close | 22.32 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 66.71K | Price | 22.32 |
Recom | - | SMA20 | 44.66% | SMA50 | 64.82% | SMA200 | 64.18% | Volume | 125,722 | Change | 0.00% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom. | ||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite